Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

The BiovaxID Phase 3 clinical trial is being conducted at fourteen U.S. oncology centers and 8 centers in Russia.

Applications for accelerated conditional approval of BiovaxID are planned to be submitted to both the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by mid-2008. The DMC has agreed to serve as a liaison between the Company and the FDA and the EMEA. If conditionally approved, BiovaxID could become commercially available in early 2009.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Biovest International, Inc.

Biovest International, Inc., is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. For further information, visit the Company Web site at www.biovest.com.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company"
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:8/19/2008)...n., Aug. 19 /- VION,PHARMAC... that it had,entered into an agreement with the Du... Oncology (the "HOVON") to conduct a clinical tria... standard remission-induction,therapy in patients ...nous,leukemia (AML) and high-risk myelodysplasia (...
(Date:8/18/2008)...8 /PRNewswire-USNewswire/ -- Boston University and... Center for Human Genetics, Inc.,("CHG") and Direc...versity,announced that CHG will no longer offer t...ena Diagnostics, Inc., These patented tests inclu...d to A1555G or Connexin 26 mutations, developmenta...
(Date:8/18/2008)... with Strong Clinical Research Relationships and P...ons to Lead Commercialization, SANTA CLARA, Calif...c.,(OTC Bulletin Board: NWCI) a cardiac diagnosti...nt W. Renz has joined NewCardio as its president. ...ion effort, to include,business development, clien...
(Date:8/15/2008)...Aug. 15 /- Globus Medical, Inc., the ... in the world, today announced,that the first FLEX...der an,Investigational Device Exemption ("IDE") re...and Dr. Rhett Murray., The FLEXUS(TM) Spacer is p...us processes with minimal disruption to the surrou...
Breaking Medicine Technology:Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 2Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy 3Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4First FLEXUS(TM) Interspinous Spacer Surgeries for IDE Clinical Trial 2Principle of Recursive Genome Function Supersedes Dogmas 3B By Andras Pellionisz Online Ahead of Print 3B 28Scientific Visionary Vindicated 29 6587 1Principle of Recursive Genome Function Supersedes Dogmas 3B By Andras Pellionisz Online Ahead of Print 3B 28Scientific Visionary Vindicated 29 6587 2Principle of Recursive Genome Function Supersedes Dogmas 3B By Andras Pellionisz Online Ahead of Print 3B 28Scientific Visionary Vindicated 29 6587 3Principle of Recursive Genome Function Supersedes Dogmas 3B By Andras Pellionisz Online Ahead of Print 3B 28Scientific Visionary Vindicated 29 6587 4Principle of Recursive Genome Function Supersedes Dogmas 3B By Andras Pellionisz Online Ahead of Print 3B 28Scientific Visionary Vindicated 29 6587 5Tips on how to build a better home for biological parts 4079 1Tips on how to build a better home for biological parts 4079 2Tips on how to build a better home for biological parts 4079 3Concentric Named to List of Top 60 Healthcare Agencies in U S 24118 1Concentric Named to List of Top 60 Healthcare Agencies in U S 24118 2MDCT virtual gastroscopy and MPR images differentiate malignant and benign gastric ulcers 24114 1
...e than half of infertile couples willing to,donate...Md., June 20, 2007 /PRNewswire/ -- RESOLVE: The,Na...g statement,today, in anticipation of President Bu... current limitations on stem cell,research: , "Pre...fe-saving,gift the infertility community is willin...
...USINESS WIRE)--Jun 25, 2007 - Elixir,Pharmaceutica...cal,data highlighting the ability of Glufast(R) (m...ation therapy with metformin, to,manage glucose su...ed in the Abstract Book for the American Diabetes,...cago, Illinois.,Glufast is an insulin secretagogue...
Other Medicine Technology:Infertile Voice Supports Stem Cell Research: RESOLVE Calls for,Patient Options in Using Frozen Embryos 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 2Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 3Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 4Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes 5
(Date:8/20/2008)... CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ -- ...reported preliminary income from,continuing operat... $27.5,million, or $0.76 per diluted share, includ...r diluted share, related to provisions for store,c...a 6.8 percent increase,compared with income from c...
(Date:8/20/2008)...IELD, Mich., Aug. 20 /PRNewswire/ -- WXYZ- TV/Chan...lness Promotion will give thousands of,Detroit met...LTHY LIVING,FOR KIDS" program. This year the progr...m. to 5 p.m. at the Charles H. Wright Museum of Af...7, "Healthy Living for Kids",has provided free imm...
(Date:8/20/2008)...N and OTTAWA, Aug. 20 /PRNewswire-FirstCall/ -- iN...nd information portal, announced,today the third w...g a free,Nintendo Wii and Wii Fit system. The Winn...n, Michigan. iNutrition sweepstakes winner Ron Mil...excited." He then told his,son who responded with,...
(Date:8/20/2008)...PRINGS, Pa., Aug. 20 /PRNewswire-USNewswire/ -- Go... agricultural industry is struggling,with high fue...ng the need,to secure the state,s energy independe...g adults., Nearly 900 guests gathered to hear the...ay Luncheon at Ag Progress Days, Pennsylvania,s,la...
Breaking Medicine News(10 mins):Health News:Longs Drug Stores Corporation Reports Second Quarter Results 2Health News:Longs Drug Stores Corporation Reports Second Quarter Results 3Health News:Longs Drug Stores Corporation Reports Second Quarter Results 4Health News:Longs Drug Stores Corporation Reports Second Quarter Results 5Health News:Longs Drug Stores Corporation Reports Second Quarter Results 6Health News:Longs Drug Stores Corporation Reports Second Quarter Results 7Health News:Longs Drug Stores Corporation Reports Second Quarter Results 8Health News:Longs Drug Stores Corporation Reports Second Quarter Results 9Health News:Longs Drug Stores Corporation Reports Second Quarter Results 10Health News:Longs Drug Stores Corporation Reports Second Quarter Results 11Health News:Longs Drug Stores Corporation Reports Second Quarter Results 12Health News:Longs Drug Stores Corporation Reports Second Quarter Results 13Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 2Health News:WXYZ-TV/Channel 7 is 'On Your Side' With Healthy Living For Kids; Free Immunizations for Children on Sunday, August 24 at Charles H. Wright Museum of African American History 3Health News:Weight Loss and Fitness Information Site iNutrition.com Gives Away Third Nintendo Wii and Wii Fit 2Health News:Pennsylvania Governor Rendell Highlights Renewable Energy, Health Care Reform at Ag Progress Days 2
...msley who worked in developing a vaccine against t...cine against bird flu in tomatoes. // The tomato ...ther than humans. These tomatoes which are the sto...d to birds rather than injected. It is a very si...
...ew drug users who have HIV, and currently has reco... // This rise in drug users is being attributed t... with crack cocaine, according to reports from The...on among injecting drug users did not change much ...
...g a big leap forward to launch Europe into Quality...are significant contributors to the economic and s...te this knowledge, very little research has been i...processes that produce knowledge. The need of th...
...ge of Wisconsin Center for Patient Care and Outcom...st cancer survivors, who were under the care of bo...ist, had a better chance of beating their tumors a...searchers found that about two-thirds of elderly b...
Other Medicine News:
Inquire
The Perfect Single basic Vac Manifold is used to process a single 96-well plate; processing time is approximately 30 minutes.
The Perfect Single Vac Manifold is available to process one 96-well plate in 30 minutes; the manifold is designed with an "open/closed" switch and a vacuum regulator with gauge for easy operation. co
...from Caliper provide an automated alternative to K...low-Down Evaporators. For over ten years TurboVap ...laim with over 4,000 units in use around the world... ...
Medicine Products: